Skip to main content
Top
Published in: Gut Pathogens 1/2022

Open Access 01-12-2022 | Helicobacter Pylori | Research

Helicobacter pylori infection: is there circulating vacuolating cytotoxin A or cytotoxin-associated gene A protein?

Authors: Ichiro Imoto, Satoko Oka, Masaki Katsurahara, Misaki Nakamura, Taro Yasuma, Junko Akada, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Noriyuki Horiki, Esteban C. Gabazza, Yoshio Yamaoka

Published in: Gut Pathogens | Issue 1/2022

Login to get access

Abstract

Background

Helicobacter pylori infection is a well-recognized cause of gastric diseases, including chronic gastritis, peptic ulcer, and gastric cancer. Vacuolating cytotoxin-A (VacA) and cytotoxin-associated gene A protein (CagA) play a role in the pathogenesis of H. pylori-related gastric diseases. Also, extragastric disorders are frequent morbid complications in patients with H. pylori infection. However, the direct pathologic implication of these virulence factors in extragastric manifestations remains unclear. Our hypothesis in the present study is that VacA and CagA released by H. pylori in the gastric mucosa leak into the systemic circulation, and therefore they can be measured in serum.

Results

Sixty-two subjects were enrolled. They were allocated into the H. pylori-positive and H. pylori-negative groups. VacA and CagA were measured by immunoassays. The serum levels of VacA and CagA above an upper limit cut-off (mean plus two standard deviations of the mean in patients without H. pylori infection) were considered positive for antigen circulating level. Five out of 25 H. pylori-positive patients were positive for both serum VacA and serum CagA. The serum levels of VacA and CagA were significantly correlated with the serum levels of anti- H. pylori antibody and interleukin-12p70 among all H. pylori-positive and H. pylori-negative patients.

Conclusions

This study suggests that spill-over of VacA and CagA antigens in the systemic circulation may occur in some patients with H. pylori infection.
Literature
1.
go back to reference Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49(1):1–8.CrossRefPubMed Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49(1):1–8.CrossRefPubMed
2.
go back to reference Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.CrossRefPubMed Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.CrossRefPubMed
4.
go back to reference Yamaoka Y. How to eliminate gastric cancer-related death worldwide? Nat Rev Clin Oncol. 2018;15(7):407–8.CrossRefPubMed Yamaoka Y. How to eliminate gastric cancer-related death worldwide? Nat Rev Clin Oncol. 2018;15(7):407–8.CrossRefPubMed
5.
go back to reference Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71(5):437–9.CrossRefPubMedPubMedCentral Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71(5):437–9.CrossRefPubMedPubMedCentral
6.
go back to reference Chen J, Xing Y, Zhao L, Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis. J Diabetes Res. 2019;2019:3705264.CrossRefPubMedPubMedCentral Chen J, Xing Y, Zhao L, Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis. J Diabetes Res. 2019;2019:3705264.CrossRefPubMedPubMedCentral
7.
go back to reference Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, et al. H. pylori and Parkinson’s disease: meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16–24.CrossRefPubMed Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, et al. H. pylori and Parkinson’s disease: meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16–24.CrossRefPubMed
8.
go back to reference Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(50): e18348.CrossRefPubMed Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(50): e18348.CrossRefPubMed
9.
go back to reference Kim BJ, Kim HS, Jang HJ, Kim JH. Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: a meta-analysis of randomized trials. Gastroenterol Res Pract. 2018;2018:6090878.CrossRefPubMedPubMedCentral Kim BJ, Kim HS, Jang HJ, Kim JH. Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: a meta-analysis of randomized trials. Gastroenterol Res Pract. 2018;2018:6090878.CrossRefPubMedPubMedCentral
10.
go back to reference Shi H, Li Y, Dong C, Si G, Xu Y, Peng M, Li Y. Helicobacter pylori infection and the progression of atherosclerosis: a systematic review and meta-analysis. Helicobacter. 2021;27:e12865.PubMed Shi H, Li Y, Dong C, Si G, Xu Y, Peng M, Li Y. Helicobacter pylori infection and the progression of atherosclerosis: a systematic review and meta-analysis. Helicobacter. 2021;27:e12865.PubMed
11.
go back to reference Yu M, Zhang R, Ni P, Chen S, Duan G. Helicobacter pylori infection and psoriasis: a systematic review and meta-analysis. Medicina (Kaunas). 2019;55(10):645.CrossRefPubMedPubMedCentral Yu M, Zhang R, Ni P, Chen S, Duan G. Helicobacter pylori infection and psoriasis: a systematic review and meta-analysis. Medicina (Kaunas). 2019;55(10):645.CrossRefPubMedPubMedCentral
12.
go back to reference Yu Y, Yao X, Liang J, Lu C, Yan T, Lin J. Is Helicobacter pylori associated with Behcet’s syndrome? A meta-analysis. Helicobacter. 2019;24(6): e12663.CrossRefPubMed Yu Y, Yao X, Liang J, Lu C, Yan T, Lin J. Is Helicobacter pylori associated with Behcet’s syndrome? A meta-analysis. Helicobacter. 2019;24(6): e12663.CrossRefPubMed
13.
go back to reference Zeng J, Liu H, Liu X, Ding C. The relationship between helicobacter pylori infection and open-angle glaucoma: a meta-analysis. Invest Ophthalmol Vis Sci. 2015;56(9):5238–45.CrossRefPubMed Zeng J, Liu H, Liu X, Ding C. The relationship between helicobacter pylori infection and open-angle glaucoma: a meta-analysis. Invest Ophthalmol Vis Sci. 2015;56(9):5238–45.CrossRefPubMed
14.
go back to reference Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol. 1988;26(2):93–9.CrossRefPubMed Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol. 1988;26(2):93–9.CrossRefPubMed
15.
go back to reference Li Q, Liu J, Gong Y, Yuan Y. Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: a meta-analysis. Medicine (Baltimore). 2017;96(17): e6620.CrossRefPubMed Li Q, Liu J, Gong Y, Yuan Y. Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: a meta-analysis. Medicine (Baltimore). 2017;96(17): e6620.CrossRefPubMed
16.
go back to reference Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50–63.CrossRefPubMed Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50–63.CrossRefPubMed
17.
18.
go back to reference Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5(4):400–4.CrossRefPubMedPubMedCentral Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5(4):400–4.CrossRefPubMedPubMedCentral
19.
go back to reference Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(3):87–96.CrossRef Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(3):87–96.CrossRef
20.
go back to reference Yagi K, Aruga Y, Nakamura A, Sekine A. Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of Helicobacter pylori-negative normal stomach and its relationship with esophago-gastric adenocarcinoma. J Gastroenterol. 2005;40(5):443–52.CrossRefPubMed Yagi K, Aruga Y, Nakamura A, Sekine A. Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of Helicobacter pylori-negative normal stomach and its relationship with esophago-gastric adenocarcinoma. J Gastroenterol. 2005;40(5):443–52.CrossRefPubMed
21.
go back to reference Kono S, Gotoda T, Yoshida S, Oda I, Kondo H, Gatta L, et al. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World J Gastroenterol. 2015;21(46):13113–23.CrossRefPubMedPubMedCentral Kono S, Gotoda T, Yoshida S, Oda I, Kondo H, Gatta L, et al. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World J Gastroenterol. 2015;21(46):13113–23.CrossRefPubMedPubMedCentral
22.
go back to reference Nishizawa T, Sakitani K, Suzuki H, Yamakawa T, Takahashi Y, Yamamichi N, et al. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H. pylori. United European Gastroenterol J. 2019;7(3):343–8.CrossRefPubMedPubMedCentral Nishizawa T, Sakitani K, Suzuki H, Yamakawa T, Takahashi Y, Yamamichi N, et al. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H. pylori. United European Gastroenterol J. 2019;7(3):343–8.CrossRefPubMedPubMedCentral
23.
go back to reference Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.CrossRefPubMed Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.CrossRefPubMed
24.
go back to reference Shimatani T, Inoue M, Iwamoto K, Hyogo H, Yokozaki M, Saeki T, et al. Prevalence of Helicobacter pylori infection, endoscopic findings and dyspeptic symptoms among a young Japanese poipulation born in the 1970s. J Gastroenterol Hepatol. 2005;20(9):1352–77.CrossRefPubMed Shimatani T, Inoue M, Iwamoto K, Hyogo H, Yokozaki M, Saeki T, et al. Prevalence of Helicobacter pylori infection, endoscopic findings and dyspeptic symptoms among a young Japanese poipulation born in the 1970s. J Gastroenterol Hepatol. 2005;20(9):1352–77.CrossRefPubMed
25.
go back to reference Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, et al. Association between gastric cancer risk and serum Helicobacter pylori antibody titers. Gastroenterol Res Pract. 2017;2017:1286198.CrossRefPubMedPubMedCentral Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, et al. Association between gastric cancer risk and serum Helicobacter pylori antibody titers. Gastroenterol Res Pract. 2017;2017:1286198.CrossRefPubMedPubMedCentral
26.
go back to reference Faul F, Erdfelder E, Lang A-G, Buchner A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRefPubMed Faul F, Erdfelder E, Lang A-G, Buchner A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRefPubMed
27.
go back to reference Denic M, Touati E, De Reuse H. Review: Pathogenesis of Helicobacter pylori infection. Helicobacter. 2020;25(Suppl 1): e12736.PubMed Denic M, Touati E, De Reuse H. Review: Pathogenesis of Helicobacter pylori infection. Helicobacter. 2020;25(Suppl 1): e12736.PubMed
28.
go back to reference Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, Maciejewski R. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2020;10(1):27.CrossRefPubMedPubMedCentral Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, Maciejewski R. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2020;10(1):27.CrossRefPubMedPubMedCentral
29.
go back to reference Raju D, Hussey S, Ang M, Terebiznik MR, Sibony M, Galindo-Mata E, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142(5):1160–71.CrossRefPubMed Raju D, Hussey S, Ang M, Terebiznik MR, Sibony M, Galindo-Mata E, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142(5):1160–71.CrossRefPubMed
30.
go back to reference Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: extragastric diseases and Helicobacter pylori. Helicobacter. 2020;25(Suppl 1): e12741.PubMed Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: extragastric diseases and Helicobacter pylori. Helicobacter. 2020;25(Suppl 1): e12741.PubMed
31.
go back to reference Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40–6.CrossRefPubMed Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40–6.CrossRefPubMed
32.
go back to reference Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, Dallio M, Federico A, Romano M. Extra-gastric manifestations of Helicobacter pylori infection. J Clin Med. 2020;9(12):3887.CrossRefPubMedPubMedCentral Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, Dallio M, Federico A, Romano M. Extra-gastric manifestations of Helicobacter pylori infection. J Clin Med. 2020;9(12):3887.CrossRefPubMedPubMedCentral
33.
go back to reference Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2011;16(Suppl 1):65–9.CrossRefPubMed Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2011;16(Suppl 1):65–9.CrossRefPubMed
34.
go back to reference Gravina A, Federico A, Ruocco E, Lo Schiavo A, Masarone M, Tuccillo C, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J. 2015;3(1):17–24.CrossRefPubMedPubMedCentral Gravina A, Federico A, Ruocco E, Lo Schiavo A, Masarone M, Tuccillo C, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J. 2015;3(1):17–24.CrossRefPubMedPubMedCentral
35.
go back to reference Suvajdzic N, Stankovic B, Artiko V, Cvejic T, Bulat V, Bakrac M, Colovic M, Obradovic V, Atkinson HD. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets. 2006;17(4):227–30.CrossRefPubMed Suvajdzic N, Stankovic B, Artiko V, Cvejic T, Bulat V, Bakrac M, Colovic M, Obradovic V, Atkinson HD. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets. 2006;17(4):227–30.CrossRefPubMed
36.
go back to reference Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166–75.CrossRefPubMed Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166–75.CrossRefPubMed
37.
go back to reference Shimoda A, Ueda K, Nishiumi S, Murata-Kamiya N, Mukai SA, Sawada S, Azuma T, Hatakeyama M, Akiyoshi K. Exosomes as nanocarriers for systemic delivery of the Helicobacter pylori virulence factor CagA. Sci Rep. 2016;6:18346. CrossRefPubMedPubMedCentral Shimoda A, Ueda K, Nishiumi S, Murata-Kamiya N, Mukai SA, Sawada S, Azuma T, Hatakeyama M, Akiyoshi K. Exosomes as nanocarriers for systemic delivery of the Helicobacter pylori virulence factor CagA. Sci Rep. 2016;6:18346. CrossRefPubMedPubMedCentral
38.
go back to reference Al-Sammak F, Kalinski T, Weinert S, Link A, Wex T, Malfertheiner P. Gastric epithelial expression of IL-12 cytokine family in Helicobacter pylori infection in human: is it head or tail of the coin? PLoS ONE. 2013;8(9): e75192.CrossRefPubMedPubMedCentral Al-Sammak F, Kalinski T, Weinert S, Link A, Wex T, Malfertheiner P. Gastric epithelial expression of IL-12 cytokine family in Helicobacter pylori infection in human: is it head or tail of the coin? PLoS ONE. 2013;8(9): e75192.CrossRefPubMedPubMedCentral
39.
go back to reference Blanchard TG, Czinn SJ. Review article: Immunological determinants that may affect the Helicobacter pylori cancer risk. Aliment Pharmacol Ther. 1998;12(Suppl 1):83–90.CrossRefPubMed Blanchard TG, Czinn SJ. Review article: Immunological determinants that may affect the Helicobacter pylori cancer risk. Aliment Pharmacol Ther. 1998;12(Suppl 1):83–90.CrossRefPubMed
Metadata
Title
Helicobacter pylori infection: is there circulating vacuolating cytotoxin A or cytotoxin-associated gene A protein?
Authors
Ichiro Imoto
Satoko Oka
Masaki Katsurahara
Misaki Nakamura
Taro Yasuma
Junko Akada
Corina N. D’Alessandro-Gabazza
Masaaki Toda
Noriyuki Horiki
Esteban C. Gabazza
Yoshio Yamaoka
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2022
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-022-00519-8

Other articles of this Issue 1/2022

Gut Pathogens 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.